echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Hanyu Pharmaceutical Co., Ltd. will obtain the production approval this year

    Hanyu Pharmaceutical Co., Ltd. will obtain the production approval this year

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hanyu pharmaceutical said at the 2013 performance presentation that the company's heavyweight new drug enkephalin will be approved this year

    Enkephalin injection has the effect of anti platelet aggregation

    It was first listed in the United States in 1998

    In 2007, the sales amount of the product in the United States reached 332 million US dollars

    At present, there is no domestic enterprise to produce the product

    Hanyu pharmaceutical declared the clinical approval documents of enkephalin API and injection in October 2005, and was approved to carry out clinical trials in July 2006; it declared production in March 2010, and has been required to submit technical supplementary data twice so far, and the approval time of the products has been correspondingly delayed

    Previously, Hanyu pharmaceutical executives had said that enkephalin is a PCI (coronary intervention) surgical drug, with a large market

    After being listed, it is expected to catch up with the bidding work of each province next year

    Combined with the company's Hospital advantages in peptide field, the market scale of enkephalin may reach 1 billion yuan

    The existing peptide drugs of Hanyu pharmaceutical industry include thymopentin for injection, somatostatin for injection, deammopressin acetate injection and terlipressin for injection

    In addition to enkephalin injection, the new heavyweight polypeptide products under research also include new drugs such as carbetoxine, atroxaban acetate injection, cetrix for injection, etc., and are also applying for production approval

    According to the public information, by 2012, the overall sales scale of China's chemical synthetic peptide drug market has exceeded 10 billion yuan.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.